Please assess the completion status of the following clinical trial:

Trial Title: The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be aged 18 years or above at baseline~* Diagnosed with any hepatobiliary condition requiring an elective major surgical resection under general anaesthetic.~* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol~Exclusion Criteria:~* Allergy/sensitivity to naloxone~* Female subjects who are pregnant or breast-feeding.~* Subjects who have received any other investigational agent within 2 months~* Subjects taking anticonvulsant medications for epilepsy~* Subjects who have a cardiac arrhythmia with an uncontrolled rate~* Subjects who have a history of chronic opioid use / chronic pain~* Any contraindication to intrathecal injection eg coagulopathy~* Documented history of obstructive sleep apnoea~* Treating clinician feels not in the patients best interests to be randomised

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naloxone (Type: EXPERIMENTAL): The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution.
- Saline (Type: PLACEBO_COMPARATOR): The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).